1ST Biotherapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
1ST Biotherapeutics, Inc. - overview
Established
2016
Location
Yongin-si, Gyeonggi do, South Korea
Primary Industry
Biotechnology
About
Founded in 2016 by Jamie Jae Eun Kim, President and CEO, 1ST Biotherapeutics, Inc. , is headquartered in Gyeonggi‑do, South Korea, specializes in the development of therapeutics addressing critical medical needs. In January 2026, 1ST Biotherapeutics, Inc. raised KRW 31.
7 billion in series D funding co-led by Groom Investment, Double Capital, and Smilegate Investment, with participation from Anda Investment Partners, DAYLI Partners, LigaChem Biosciences Inc. , Mirae Asset Securities, CKD Venture Capital, ANDA Asset Management, Woori Investment Securities, Wanted Lab Partners, and Korea Investment & Securities. 1ST Biotherapeutics specializes in the discovery and development of therapeutics aimed at addressing critical unmet medical needs in neurodegenerative diseases, immuno-oncology, and rare diseases. Their portfolio includes drug candidates that leverage advances in genomic-based target discovery and biomarker identification, with a focus on improving patient treatment outcomes.
The company collaborates with healthcare providers, research institutions, and pharmaceutical partners, primarily in North America, Europe, and Asia. As of 2024, the company reported EBITDA of KRW 12,615,595. 289. Revenue generation is based on strategic partnerships and collaborations, with a structure likely revolving around milestone payments and potential royalties from successful product developments.
The company will use the January 2026 funding to support its growth and further development of its clinical capabilities.
Current Investors
KB Investment, InterVest, Smilegate Investment
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.1stbio.com
Company Stage
Series D
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.